RESUMO
BACKGROUND: Giant basal cell carcinoma, in which the tumour measures 5 cm or greater in diameter, is a very rare skin malignancy that accounts for less than 1 per cent of all basal cell tumours. Very few studies have reported on the incidence, resection and reconstruction of this lesion worldwide. METHODS: In total, 17 patients with giant basal cell carcinoma of the head and neck region underwent surgical excision and reconstruction at our hospital. Medical charts were retrospectively reviewed and analysed. RESULTS: The lesion was usually in the forehead, eyelid, lips or nasal-cheek region. The greatest diameter ranged from 5 to 11 cm, with 5-6 cm being the most common size at the time of presentation. All patients had their tumour resected and reconstructed in a single-stage procedure, mostly with a local advancement flap, and with no post-operative flap failure. CONCLUSION: Giant basal cell carcinoma of the head and neck can be successfully treated with a local flap in a single-stage approach.
Assuntos
Carcinoma Basocelular/patologia , Carcinoma Basocelular/cirurgia , Neoplasias Faciais/patologia , Neoplasias Faciais/cirurgia , Procedimentos de Cirurgia Plástica , Neoplasias Cutâneas/cirurgia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Neoplasias Cutâneas/patologia , Retalhos Cirúrgicos , Resultado do TratamentoAssuntos
Carcinoma Basocelular/cirurgia , Procedimentos Cirúrgicos Dermatológicos/métodos , Cirurgia de Mohs/métodos , Procedimentos de Cirurgia Plástica/métodos , Neoplasias Cutâneas/cirurgia , Idoso , Carcinoma Basocelular/patologia , Face , Estudos de Viabilidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Neoplasias Cutâneas/patologia , Resultado do Tratamento , Carga TumoralRESUMO
Living donor liver transplantation (LDLT) offers timely transplantation for patients with hepatocellular carcinoma (HCC). If ABO-incompatible LDLT is feasible, the need for pretransplantation treatment may be eliminated, which may reduce overall morbidity. In this article, we have described 8 adult HCC patients who successfully underwent LDLT from ABO-incompatible donors. Antirejection therapy included multiple preoperative plasmaphereses, splenectomy, and an immunosuppressive regimen with tacrolimus, methylprednisolone, and mycophenolate mofetil. The maintenance dose of immunosuppression did not differ from that of the ABO-identical cases. In addition, we also performed intrahepatic arterial infusion of prostaglandin E1. In 5 patients, we administered a single dose of rituximab, a chimeric CD20 monoclonal antibody. As a result of this treatment, 6/8 patients are still alive. Our experience has shown that it is possible to control antibody-mediated humoral rejection and other complications in adult ABO-incompatible LDLT.
